Literature DB >> 8829184

Sialyl Lewis(a) ganglioside in pancreatic cancer tissue correlates with the serum CA 19-9 level.

Y Hamanaka1, S Hamanaka, M Suzuki.   

Abstract

CA 19-9 ganglioside antigen was extracted from the tumors of 16 patients with pancreatic cancer and the antigen was confirmed by mass spectrometry to be a sialyl Lewis(a) ganglioside. Ductal adenocarcinomas from four patients, two whose Lewis blood phenotype was Le(a- b-), one with undifferentiated carcinoma, and one with an acinar cell carcinoma, did not contain detectable amounts of sialyl Le(a) ganglioside. A significant correlation was found between serum CA 19-9 levels and the recovery of ganglioside antigen from respective tumors, but not tumor burden.

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8829184     DOI： 10.1097/00006676-199608000-00007

Source DB:  PubMed          Journal:  Pancreas        ISSN： 0885-3177            Impact factor:   3.327


  7 in total

1.  Current Status and Future Directions for Screening Patients at High Risk for Pancreatic Cancer.

Authors:  Florencia McAllister; Maria F Montiel; Guneesh S Uberoi; Angad S Uberoi; Anirban Maitra; Manoop S Bhutani
Journal:  Gastroenterol Hepatol (N Y)       Date:  2017-05

2.  Glycan motif profiling reveals plasma sialyl-lewis x elevations in pancreatic cancers that are negative for sialyl-lewis A.

Authors:  Huiyuan Tang; Sudhir Singh; Katie Partyka; Doron Kletter; Peter Hsueh; Jessica Yadav; Elliot Ensink; Marshall Bern; Galen Hostetter; Douglas Hartman; Ying Huang; Randall E Brand; Brian B Haab
Journal:  Mol Cell Proteomics       Date:  2015-03-02       Impact factor: 5.911

Review 3.  The clinical utility of CA 19-9 in pancreatic adenocarcinoma: diagnostic and prognostic updates.

Authors:  Katherine E Poruk; D Z Gay; K Brown; J D Mulvihill; K M Boucher; C L Scaife; M A Firpo; S J Mulvihill
Journal:  Curr Mol Med       Date:  2013-03       Impact factor: 2.222

4.  Circulating cancer-associated extracellular vesicles as early detection and recurrence biomarkers for pancreatic cancer.

Authors:  Yusuke Yoshioka; Manami Shimomura; Keigo Saito; Hideshi Ishii; Yuichiro Doki; Hidetoshi Eguchi; Tetsuya Nakatsura; Takao Itoi; Masahiko Kuroda; Masaki Mori; Takahiro Ochiya
Journal:  Cancer Sci       Date:  2022-08-11       Impact factor: 6.518

5.  Altered sphingolipid metabolism in patients with metastatic pancreatic cancer.

Authors:  Yixing Jiang; Nicole A DiVittore; Megan M Young; Zhiliang Jia; Keping Xie; Timothy M Ritty; Mark Kester; Todd E Fox
Journal:  Biomolecules       Date:  2013-07-25

Review 6.  Diagnostic and prognostic value of carcinoembryonic antigen in pancreatic cancer: a systematic review and meta-analysis.

Authors:  Qingcai Meng; Si Shi; Chen Liang; Dingkong Liang; Wenyan Xu; Shunrong Ji; Bo Zhang; Quanxing Ni; Jin Xu; Xianjun Yu
Journal:  Onco Targets Ther       Date:  2017-09-15       Impact factor: 4.147

7.  Novel Autoantibody Signatures in Sera of Patients with Pancreatic Cancer, Chronic Pancreatitis and Autoimmune Pancreatitis: A Protein Microarray Profiling Approach.

Authors:  Sahar Ghassem-Zadeh; Katrin Hufnagel; Andrea Bauer; Jean-Louis Frossard; Masaru Yoshida; Hiromu Kutsumi; Hans Acha-Orbea; Matthias Neulinger-Muñoz; Johannes Vey; Christoph Eckert; Oliver Strobel; Jörg D Hoheisel; Klaus Felix
Journal:  Int J Mol Sci       Date:  2020-03-31       Impact factor: 5.923
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.